We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alnylam Receives Grant of new Patent Broadly Covering RNAi Therapeutics
News

Alnylam Receives Grant of new Patent Broadly Covering RNAi Therapeutics

Alnylam Receives Grant of new Patent Broadly Covering RNAi Therapeutics
News

Alnylam Receives Grant of new Patent Broadly Covering RNAi Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alnylam Receives Grant of new Patent Broadly Covering RNAi Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alnylam Pharmaceuticals, Inc. has announced the first grant for the Kay & McCaffrey patent. The patent is an early, “fundamental” patent in the RNAi therapeutics field based on the groundbreaking research by Drs. Anton McCaffrey and Mark Kay who were amongst the first to demonstrate the ability to harness RNA interference in a living mammal. The Kay & McCaffrey patent is licensed exclusively to Alnylam through an agreement with Stanford University.

The Kay & McCaffrey patent was granted after examination by the Australian Patent Office with 38 claims that broadly cover methods and compositions of RNAi therapeutics, including a method of reducing expression of a coding sequence in a target mammalian cell with a double-stranded RNA of between 15 and 25 nucleotides in length.

In addition, the patent includes claims covering small interfering RNAs and short hairpin RNAs. The Kay & McCaffrey patent series, with these and additional claim sets, is pending in other jurisdictions, including the U.S., EU, and Japan.

“We are delighted to add the Kay & McCaffrey patent to the broader portfolio of Alnylam held patents that comprise intellectual property (IP) which we believe is fundamental for the development and commercialization of all RNAi therapeutics,” said Barry Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals.

“This new grant, the first for the Kay & McCaffrey series, expands the scope of our fundamental IP estate that also includes issued or granted patents from the Crooke, Kreutzer-Limmer, and Tuschl II estates. Of course, we have a clear track record of leveraging our patent portfolio to enable the field and provide freedom to operate for RNAi therapeutics, as evidenced by more than 25 licensing agreements which have yielded over $660 million in realized cash funding. With this and the continued expansion of our IP estate, we expect our business development execution to only continue in the future.”
Advertisement